NDAORALCAPSULE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Cardiac Myosin Inhibitors
Pharmacologic Class:
Cardiac Myosin Inhibitor
Indications (1)
Clinical Trials (5)
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Started Jan 2026
500 enrolled
Hypertrophic Cardiomyopathy
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
Started Sep 2025
50 enrolled
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Started May 2025
200 enrolled
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Started Jul 2024
600 enrolled
Obstructive Hypertrophic Cardiomyopathy
Real-World Effectiveness of Mavacamten in Canada
Started Jun 2024
115 enrolled
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Loss of Exclusivity
LOE Date
Apr 28, 2036
123 months away
Patent Expiry
Apr 28, 2036
Exclusivity Expiry
Apr 28, 2029